Literature DB >> 21900904

Nonprofit disease groups earmark grants for drug repositioning.

Elie Dolgin.   

Abstract

Mesh：

Year:  2011        PMID： 21900904     DOI： 10.1038/nm0911-1027

Source DB:  PubMed          Journal:  Nat Med        ISSN： 1078-8956            Impact factor:   53.440


× No keyword cloud information.
  2 in total

1.  Chemical genomic profiling for antimalarial therapies, response signatures, and molecular targets.

Authors:  Jing Yuan; Ken Chih-Chien Cheng; Ronald L Johnson; Ruili Huang; Sittiporn Pattaradilokrat; Anna Liu; Rajarshi Guha; David A Fidock; James Inglese; Thomas E Wellems; Christopher P Austin; Xin-zhuan Su
Journal:  Science       Date:  2011-08-05       Impact factor: 47.728

2.  The NCGC pharmaceutical collection: a comprehensive resource of clinically approved drugs enabling repurposing and chemical genomics.

Authors:  Ruili Huang; Noel Southall; Yuhong Wang; Adam Yasgar; Paul Shinn; Ajit Jadhav; Dac-Trung Nguyen; Christopher P Austin
Journal:  Sci Transl Med       Date:  2011-04-27       Impact factor: 17.956
  2 in total
  5 in total

1.  Drug Repurposing from an Academic Perspective.

Authors:  Tudor I Oprea; Julie E Bauman; Cristian G Bologa; Tione Buranda; Alexandre Chigaev; Bruce S Edwards; Jonathan W Jarvik; Hattie D Gresham; Mark K Haynes; Brian Hjelle; Robert Hromas; Laurie Hudson; Debra A Mackenzie; Carolyn Y Muller; John C Reed; Peter C Simons; Yelena Smagley; Juan Strouse; Zurab Surviladze; Todd Thompson; Oleg Ursu; Anna Waller; Angela Wandinger-Ness; Stuart S Winter; Yang Wu; Susan M Young; Richard S Larson; Cheryl Willman; Larry A Sklar
Journal:  Drug Discov Today Ther Strateg       Date:  2011

Review 2.  A synopsis on the role of tyrosine hydroxylase in Parkinson's disease.

Authors:  Shams Tabrez; Nasimudeen R Jabir; Shazi Shakil; Nigel H Greig; Qamre Alam; Adel M Abuzenadah; Ghazi A Damanhouri; Mohammad A Kamal
Journal:  CNS Neurol Disord Drug Targets       Date:  2012-06-01       Impact factor: 4.388

3.  Rifampin inhibits Toll-like receptor 4 signaling by targeting myeloid differentiation protein 2 and attenuates neuropathic pain.

Authors:  Xiaohui Wang; Peter M Grace; Michael N Pham; Kui Cheng; Keith A Strand; Christina Smith; Jing Li; Linda R Watkins; Hang Yin
Journal:  FASEB J       Date:  2013-04-08       Impact factor: 5.191

4.  A staged screening of registered drugs highlights remyelinating drug candidates for clinical trials.

Authors:  C Eleuteri; S Olla; C Veroni; R Umeton; R Mechelli; S Romano; M C Buscarinu; F Ferrari; G Calò; G Ristori; M Salvetti; C Agresti
Journal:  Sci Rep       Date:  2017-04-07       Impact factor: 4.379

Review 5.  Setting a research agenda for progressive multiple sclerosis: the International Collaborative on Progressive MS.

Authors:  Robert J Fox; Alan Thompson; David Baker; Peer Baneke; Doug Brown; Paul Browne; Dhia Chandraratna; Olga Ciccarelli; Timothy Coetzee; Giancarlo Comi; Anthony Feinstein; Raj Kapoor; Karen Lee; Marco Salvetti; Kersten Sharrock; Ahmed Toosy; Paola Zaratin; Kim Zuidwijk
Journal:  Mult Scler       Date:  2012-08-23       Impact factor: 6.312
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.